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Background: The seventh TNM edition introduced a new, specific staging structure for intrahepatic
cholangiocarcinoma (IHC).
Objective: To compare the accuracy of the sixth and the new seventh edition to predict survival after
hepatectomy for IHC.
Methods: In all, 434 consecutive patients who underwent hepatectomy at 16 tertiary-care centres
(1990–2008) were identified. End points were overall (OS) and recurrence-free survival (RFS) for both T
cohorts and stage strata.
Results: After a median follow-up of 32.4 months, 3- and 5-year OS and RFS estimates were 47.1% and
32.9%, and 26.5% and 19.1%, respectively. Overall, both the editions were statistically significant
discriminators of OS and RFS (P < 0.05). However, the survival curves of the new T2a and T2b cohorts
appear superimposed. Conversely, the old T2 and T3 cohorts accurately stratify patients into distinct
prognostic groups (P < 0.01). The seventh edition does not show monotonicity of gradients (the T4
category demonstrates significantly better OS and RFS compared with T2 patients). The seventh edition
stage I and II are significantly different whereas the old stage I and II were not.
Conclusions: The new seventh edition of the AJCC/UICC Staging System proved to be adequate
although further studies are need to confirm its superiority compared with the previous edition.
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Introduction
Intrahepatic cholangiocarcinoma (IHC) is the second common-
est primary malignant neoplasm of the liver, originating from the
epithelium of the second-order or more proximal bile ducts.
Although rising incidence rates, paralleled by mortality rates,
have been documented in most areas worldwide,1,2 IHC remains
a rare disease when compared with hepatocellular carcinoma
(HCC). Data from the 17th nationwide follow-up survey of
primary liver cancer in Japan indicate that IHC accounts for only
4.1% of the newly diagnosed liver tumours.3 In non-endemic
geographical regions, such as the United States, this proportion is
estimated to be slightly higher (approximately 10%).1 The rarity
of the disease and the frequency with which patients present at a
late, unresectable stage (80–85%),4 had hampered an in-depth
understanding of the prognostic factors associated with poor sur-
vival after resection. In western countries, the severity or stage of
an individual’s cancer has traditionally been evaluated on the
basis of the TNM staging system which classifies cancers by
the size and extent of the primary tumour (T), involvement of
regional lymph nodes (N) and the presence or absence of distant
metastases (M). In 1988, in the 3rd edition of the TNM staging
manual, the American Joint Committee on Cancer (AJCC) and
the International Union for Cancer Control (UICC) devised a
separate staging system for primary liver cancers, which applied
to both HCC and IHC. However, this original staging algorithm
as well as all subsequent revisions was based only on data
obtained from patients resected for HCC. Nonetheless, HCC and
IHC differ significantly in pathogenesis, tumour behaviour and
prognosis after surgical resection. Therefore, after two decades,
the development of a separate staging with specific relevance to
IHC was critical as information derived from staging not only
provides data regarding prognosis, but also dictates patient
stratification in clinical research. Based on the analysis of data
obtained form The Surveillance, Epidemiology, and End Results
(SEER) database on 598 unselected patients who had undergone
surgery for IHC, Nathan et al.5 proposed a new staging schema
which was adopted in the seventh edition of the TNM Staging
Manual.6 However, this novel staging system, which is indepen-
dent of the staging systems for HCC and extahepatic bile duct
malignancy, has not been externally validated nor compared with
the sixth edition classification schema.7 The purpose of the
present study was to compare the prognostic accuracy of the
sixth and the new seventh edition of the AJCC/UICC staging
systems to predict survival after liver resection for IHC in a large
series of patients treated at tertiary hepatobiliary centres.
Methods
In all, 434 consecutive patients treated with curative intent liver
resection for IHC between March 1990 and December 2008 at 16
tertiary hepatobiliary centres were identified from each institu-
tion’s prospectively collected database. Pathological data of all
patients were reviewed to confirm the diagnosis of IHC which
was based on the histopathological examination of haematoxylin
and eosin (H&E) and cytokeratin-stained sections. Patients with
mixed IHC/HCC and hilar (Klatskin) adenocarcinomas were
considered ineligible for entering this study. Before surgery, all
Table 1 sixth and seventh edition of the AJCC/UICC TNM classification algorithm for intrahepatic cholangiocarcinoma (IHC)
sixth edition seventh edition
T1 Solitary tumour without vascular invasion T1 Solitary tumour without vascular invasion
T2 Solitary tumour with vascular invasion or
multiple tumours, none more than 5 cm
T2a Solitary tumour with vascular invasion
T3 Multiple tumours more than 5 cm or tumour involving
a major branch of the portal or hepatic veins
T2b Multiple tumours, with or without vascular invasion
T4 Tumour(s) with direct invasion of adjacent
organs other than the gallbladder or with
perforation of visceral peritoneum
T3 Tumour(s) perforating the visceral peritoneum
or involving the local extra hepatic structures
by direct invasion
T4 Tumour with periductal invasion
N0 no regional lymph node metastases N0 no regional lymph node metastases
N1 regional lymph node metastases N1 regional lymph node metastases
M0 no regional lymph node metastases M0 no regional lymph node metastases
M1 regional lymph node metastases M1 regional lymph node metastases
Stage Stage
I T1 N0 M0 I T1 N0 M0
II T2 N0 M0 II T2 N0 M0
IIIa T3 N0 M0 III T3 N0 M0
IIIb T4 N0 M0 IVa T4 N0 M0, Any T N1 Mo
IIIc Any T N1 M0 IVb Any T, Any N, M1
IV Any T, Any N, M1
HPB 199
HPB 2011, 13, 198–205 © 2011 International Hepato-Pancreato-Biliary Association
patients received routine clinical evaluation including medical
history, physical examination, assessment of serum laboratory
tests, colonoscopy and upper gastrointestinal (GI) endoscopy and
appropriate imaging studies [e.g. computed tomography (CT)
or magnetic resonance imaging (MRI) scan of the abdomen and
chest radiography or a chest computed tomography] at the dis-
cretion of the treating physician. After surgery, patients were
followed at regular intervals of 3 to 6 months according to each
institution protocols. Follow-up data were prospectively recorded
until 31 October 2009. Relevant clinicopathological features were
collected for each patient. Specifically, these variables included:
age; gender; pre-operative serum CEA and CA19.9 concentration;
type of surgical procedures; tumour size (in patients with multiple
IHCs the largest tumour was used as the index lesion); tumour
number (as we could not retrospectively differentiate between
satellitosis, intrahepatic metastasis and multiple primary
tumours, tumours were classified as solitary vs. multiple); histo-
logical differentiation; presence of microscopic or major vascular
invasion; lymph node status; invasion of adjacent organs; and
presence of distant metastases. Patients were classified separately
according to the criteria of the sixth and the new seventh edition
of the AJCC/UICC Staging System (Table 1).
In the present study, the primary end points used to evaluate
the stratification ability of the two staging systems were OS and
RFS. Rates for these outcome measures were estimated using
the Kaplan–Meier methodology measuring time from the date
of surgery to the date of death or last follow-up, and the date of
tumour relapse at any site, respectively. For estimation of RFS,
patients who were alive and without tumour recurrence at the
time of last contact were censored. As the aim of the present study
was to investigate the performance of the two staging systems in
stratifying the long-term prognosis, patients who died in the post-
operative period (i.e within 90 days after surgery or during the
same hospital stay) were excluded. The capacity of each staging
system to distinguish categories of patients with significantly dif-
ferent survival rates was evaluated by comparing the survival
distributions within single categories using the log-rank test.
Cox’s proportional hazard regression was used to assess
the monotonicity of gradients (i.e. the median survival, either
overall or recurrence free, of patients classified within earlier
stages is longer than the survival of patients in more advanced
stages). Two sets of analyses were performed. The first focused on
the evaluation of the T categories while the second analysed the
stage strata. Of note, statistical comparisons ware made only
between groups of a minimum informative sample size of 20
patients. Statistical significance was set at P-values of <0.05. The R
environment (version 2.10.1) software package was used for sta-
tistical analyses.
Results
Patients characteristics and survival
The descriptive characteristics of the 434 patients included in the
study are summarized in Table 2. Patients were evenly distributed
Table 2 Clinical and pathologic features of the study population
Variable Value %
Age (years) 65 (29–85)
Gender (male/female) 243/191 56/44
Pre-operative serum concentration
CEA (ng/ml) 2.3 (0–36 000)
CA19.9 (U/ml) 57.1 (0.2–27 000)
Type of resection
Extended hepatectomy 84 19.4
Major hepatectomy 220 50.7
Minor hepatectomy 130 29.9
Lymph node dissection
None 121 27.9
Sampling 43 9.9
Standard 157 36.2
Extended 113 26.0
Additional abdominal procedures 134 30.9
Macroscopic type classification
Mass forming 390 89.9
Periductal infiltrating or mixed
mass forming + periductal
39 9.0
Intraductal 5 1.1
Tumour size (cm) 60 (10–250)
Tumour number
Single 293 67.5
Multiple 140 32.3
NA 1 0.2
Tumour grade
Well/moderately differentiated 259 59.7
Poorly or undifferentiated 147 33.9
NA 28 6.4
Presence of vascular invasion
Present 211 48.6
Absent 187 43.1
NA 36 8.3
Presence of perineural invasion
Present 163 37.5
Absent 183 42.2
NA 88 20.3
Lymph node status
pNx 121 27.9
pN0 193 44.5
pN1 113 26.0
NA 7 1.6
Distant metastases 14 3.2
Continuous variable are reported as median (range); NA, not available.
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as to gender (male/female ratio 1.27 : 1) with a median age of 65
(range 29–85) years. Seventy per cent of patients underwent major
(n = 220) or extended (n = 84) hepatectomies. In addition to
hepatic resection, 313 patients (72.1%) underwent hepatic pedicle
lymph node (LN) sampling (n = 43) or regional LN dissection
(n = 270). This was extended to second echelon LN in 113 patients
(41.8%). Therefore, 121 patients (27.9%) were classified as pNx.
Nodal status was pN0 in 193 patients (44.5%) whereas 113
patients (26.0%) were found to have lymph nodes metastases (the
pN status was uncertain for 7 patients who had undergone lym-
phadenectomy). In all, 134 patients (30.9%) underwent 159 addi-
tional major intraabdominal procedures of which 84 (52.8%)
were bile duct resections and 22 (13.8%) were vascular resections.
Twenty-three patients died within 90 days (mortality rate 5.3%),
leaving, for the purpose of this study, a final cohort of 411
patients.
At the time the data were censored, 218 patients (53.0%) had
died, with a median follow-up for the survivors of 36.5 (range 1 to
181) months. Overall median survival was 33 months [95% con-
fidence interval (CI) 27.0–39.1], and the 1-, 3- and 5-years overall
survival estimates were 82.3%, 47.1%, and 32.9%, respectively.
Recurrence occurred in 237 patients (57.7%) after a median of 15
months, with the liver involved in 174 patients (73.4%). In 129
(54.4%) patients this was isolated to the liver and in 45 (19.0%) it
was with disseminated disease. At last follow-up, disease recur-
rence could not be ascertained in 33 patients (8.0%), while for an
additional 13 patients (3.1%) who developed recurrence, the exact
date of recurrence could not be obtained. Therefore, these patients
were not considered for the estimation of the RFS. Median RFS
was 15.2 months (95% CI, 12.8–18.7), and the 1-, 3- and 5-years
RFS estimates were 56.1%, 26.5% and 19.1%, respectively.
Staging system comparison
Patient distribution by T classification for each system and stage
migration is shown in Table 3. Figure 1 depicts the Kaplan–Meier
estimated OS and RFS curves, according to the two different
staging systems. When comparison of survival distribution was
made using the log-rank test, both staging systems were statisti-
cally significant discriminators of both overall OS and RFS (both
P < 0.001). Only the sixth edition showed monotonicity of gradi-
ents; in fact, in the seventh edition, T4 patients had a better sur-
vival than patients classified as T2a and T2b (Table 4). In addition,
the survival curves of the new T2a and T2b cohorts appear super-
imposed. On the contrary, the old T2 and T3 cohorts accurately
stratify patients into two distinct prognostic groups (P < 0.01)
(Fig. 1 and Table 4). Similar results were obtained when the analy-
sis of OS was restricted to patients without nodal or metastatic
disease (pN0 M0) (data not shown). In the same subset of
patients, however, analysis of RFS did not show statistically sig-
nificant differences.
In order to assess the precision of prognostication of the stage
grouping of the two systems, survival analysis was restricted to 284
patients. In fact, 127 patients who survived their hepatic resection
had no pathological information on the N status and could not be
assigned to a specific stage. Figure 2 depicts the Kaplan–Meier
estimated OS and RFS curves for the two systems strata. Both
systems showed an overall significant difference in the probability
of OS across the different stages (P < 0.001) and a monotonicity of
gradients (Table 4). However, in neither edition a significant step-
wise discrimination of all stages could be demonstrated. In par-
ticular, in the sixth edition stage I and II were not sequentially
different (Table 4). Because of the small number of patients in
stages IIIb (n = 4) and IV (n = 12), no meaningful conclusions can
be driven by the comparison of stages III and IV. However, when
stage IIIa was compared with stage IIIc, OS of stage IIIc patients
was not statistically worse (P = 0.286). Conversely, the seventh
edition adequately stratified stages I and II into two distinct prog-
nostic groups, albeit the difference was marginally significant (P =
0.049). Again, stage III and IVb were too small to allow for statis-
tical analysis. When stage II was compared with stage IVa a sig-
nificant discrimination between patients was observed (P = 0.01).
Overall both staging systems were significant discriminators
for RFS (P < 0.001) and showed monotonicity of gradients for
representative strata (i.e. strata with more than 20 patients)
(Table 4). With consideration of the statistical constraints related
to stages IIIb and IV (sixth edition) and III and IVb (seventh
Table 3 Patients distribution by T classification in each system
seventh edition
si
xt
h
ed
it
io
n
T 1 2a 2b 3 4 NA n* %
1 122 14 136 33.1
2 99 38 15 152 37.0
3 12 82 7 100 24.3
4 10 2 12 2.9
NA 11 11 2.7
n* 122 110 120 10 38 11 411
% 29.7 26.8 29.2 2.4 9.2 2.7
*n, number of patients; T, category T; NA, not available.
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edition), the sixth edition accurately discriminates sequential
stages I and II, whereas stage IIIa did not differ from stage II. The
new seventh edition performed similarly with almost identical
survival estimates of stages II and IVa.
Discussion
Accurate staging after surgical resection of any cancer type is
essential to evaluate the results of treatments and clinical trials, to
provide data regarding the prognosis and to serve as a basis for
clinical and translational cancer research or registries.Over the past
20 years, staging of IHC has traditionally been defined on the basis
of an algorithm specifically developed for HCC. However, the
appropriateness of a single staging system applying to both
primary liver cancers is questionable because of the inherent dif-
ferences in the aetiology and the biological behaviour of the two
diseases.8 Previous attempts to design a specific staging algorithm
for IHC resulted in the proposal of two distinct staging systems.8,9
However, both systems were devised after analysis of a relatively
small series of patients. This may be problematic because the
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Figure 1 Kaplan–Meier estimated overall (OS) (A and B) and recurrence-free survival (RFS) (C and D) curves stratified for T categories
according to the sixth and seventh editions of the TNM Staging System. Survival curves have been truncated when the number at risk is less
than 10% of the starting denominator or less than 5
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development of a staging system should rely on the identification of
individual variables that consistently predict survival. Yet, in
patients with IHC reports on the significance of various predictors
of poor outcome are still conflicting.8–16 To overcome this limita-
tion, Nathan and colleagues5 utilized the SEER database to select a
large series of patients who had undergone liver resection for IHC.
By analysing the survival data of 598 patients, the investigators
found that tumour size had no independent effect on survival.
Because a tumour size >5 cm had no prognostic relevance, the
sixth edition AJCC/UICC T classification failed to stratify T2 and
T3 cohorts into two distinct prognostic groups. In this study, the
Cox model also revealed that both vascular invasion and
multiplicity of tumour number significantly impacted prognosis
with no additive or synergistic effect of the two factors. These
findings were integrated into a simplified staging system that omits
tumour size as a parameter to define the T categories. Although
simpler, the resulting model demonstrated similar prognostic
accuracy to the sixth edition classification scheme and represented
the basis for designing a new staging structure independent of that
for HCC. This new algorithm was incorporated into the seventh
edition of the AJCC/UICC TNM staging manual. However, since
its introduction in clinical practice, this new staging schema has not
been independently validated. Using the largest, prospectively col-
lected series of IHC resected at tertiary referral centres we sought to
critically evaluate the prognostic accuracy of the sixth and seventh
editions of the TMN classification systems.
Unexpectedly, the most significant finding of the present study
was that the old T2 and T3 categories accurately stratify patients
into two distinct prognostic groups for both OS and RFS. This is
in contrast with the results of Nathan et al.5 and may be attributed
to our cohort selection from highly specialized hepatobiliary
centres. In fact, in the current series the 5-year OS was twice that
observed in Nathan’s study (32.9%, vs. 18%). This might suggest
substantial differences in the baseline characteristics between the
two studies’ populations. However, the percentage of individuals
with LN metastases, multiple tumours, poorly differentiated or
undifferentiated tumours was similar. Likewise, the distribution
of patients after stratification for tumour diameter (2–5 cm and
>5 cm) was comparable, with a higher proportion of small IHC
(<2 cm) in the SEER population (16.5% vs. 5.1%). In a retrospec-
tive study analysing the outcome of 172 patients resected for
mass-forming IHC, tumour size <2 cm was found to be the most
important determinant of survival after multivariate analysis.8
Therefore, the substantial number of patients with small IHC in
the study by Nathan et al.5 might counterbalance the higher pro-
portion of patients with distant metastases observed in their series
(19.2% vs. 4.2% in the current series). In addition, from the meth-
odological standpoint, within the current series all pathological
data were retrospectively reviewed to confirm the diagnosis of
IHC and the consistency of the data recorded in each prospec-
tively collected database for the variables of interest. Therefore, the
number of missing values was reduced, usually because of a lack in
Table 4 Survival estimates stratified for groups in the two staging systems
sixth edition seventh edition
Class n* Median
(95% CI)
3-year
estimates
(%)
5-year
estimates
(%)
Hazards
Ratio
P valuea Class n* Median
(95% CI)
3-y
estimates
(%)
5-y
estimates
(%)
Hazards
Ratio
P valuea
O
ve
ra
ll
su
rv
iv
al
T1 136 91 44.2–137.7 68.1 55.7 1 T1 122 91 43.7–138.3 68.2 53.5 1
T2 152 30 23.7–36.2 42.8 24.7 1.89 <0.001 T2a 110 28 20.5–35.5 39.4 23.4 2.11 <0.001
T3 100 18 14.1–21.9 29.6 20.2 3.26 0.002 T2b 120 22 16.8–27.1 34.7 21.9 2.58 0.265
T4 12 – – – – – – T3 10 – – – – – –
T4 38 39 15.8–62.1 54.2 32.1 1.42 0.030
I 67 60 20.9–99.1 68.3 47.8 1 I 56 60 11.6–108.3 66.2 48.0 1
II 69 40 16.6–63.3 57.3 35.8 1.32 0.277 II 95 39 24.2–53.7 50.8 28.2 1.61 0.049
IIIa 32 20 12.1–27.8 35.4 17.7 2.65 0.034 III 3 – – – – – –
IIIb 4 – – – – – – IVa 117 19 14.6–23.3 31.3 19.0 2.63 0.420
IIIc 100 17 14.2–19.8 23.6 13.8 3.51 0.339 IVb 12 – – – – – –
IV 12 – – – – – –
R
ec
ur
re
nc
e-
fr
ee
su
rv
iv
al
T1 121 32 22.1–40.9 46.5 38.5 1 T1 108 31 22.4–39.6 44.5 38.2 1
T2 128 15 11.2–18.7 21.6 10.8 2.19 <0.001 T2a 99 12 9.3–14.7 17.2 4.3 2.71 <0.001
T3 95 9 7.6–10.3 14.1 7.5 3.58 0.001 T2b 114 10 8.1–11.9 18.5 11.6 2.54 0.700
T4 12 – – – – – – T3 10 – – – – – –
T4 25 24 4.1–43.9 45.5 31.2 1.21 0.019
I 61 27 16.4–37.5 44.9 34.9 1 I 50 24 13.9–34.0 37.5 31.2 1
II 62 18 12.4–23.5 24.2 13.4 1.75 0.010 II 89 15 10.6–19.3 19.4 12.2 1.82 0.008
IIIa 31 10 7.3–12.6 12.7 0 2.63 0.065 III 3 – – – – – –
IIIb 4 – – – – – – IVa 107 11 7.5–14.4 24.5 13.0 2.11 0.682
IIIc 91 8 5.9–10.3 16.7 6.7 3.11 0.809 IVb 9 – – – – – –
IV 9 – – – – – –
n* = number of patients; aP-values are calculated with respect to the preceding category. Survival data, HR and P-values are not reported for categories of less than 20 patients.
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the original pathology report, to an average of 6–8%. In contrast
to this, within the SEER dataset the proportion of missing values
for the most important variables was as high as 61%.
After elimination of tumour size as a parameter to designate
the T subgroups, in the seventh edition patients with multiple
tumour or vascular invasion – the old T2 and T3 patients – were
combined into a unique, broad T2 category which is sub-classified
into 2a and 2b. In the TMN philosophy, subdivisions of the main
designators should provide more specific prognostic information.
The current data indicate that these two sub-categories do not
differ with respect to long-term survival questioning the prognos-
tic appropriateness of such a separation. Nevertheless, the T2a and
T2b sub-classification might be relevant to define what type of
tumour the patient has rather than simply allocating them into a
broad category.
For representative strata, the sixth edition staging algorithm
showed monotonicity of gradients (i.e. the median survival of
patients classified within earlier stages is longer than the survival of
patients in more advanced stages) for both the T classification and
stage groupings whereas the seventh edition did not. In fact, within
the current series a significantly better OS and RFS of patients
classified as T4 as compared with patients classified as T2a or T2b
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Figure 2 Kaplan–Meier estimated overall (OS) (A and B) and recurrence-free survival (RFS) (C and D) curves stratified for stage classes
according to the sixth and seventh editions of the TNM Staging System. Survival curves have been truncated when the number at risk is less
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was observed. The provision of a separate classification into the T4
category of patients with a specific IHC subtype, the periductal-
infiltrating, represents the second characteristic feature of the new
AJCC/UICC TNM staging system. However, although limited data
definitely demonstrate a more aggressive biology of this tumour
subtype, in the seventh edition periductal-infiltrating tumours
were coded as T4 which should denote the greatest cancer extent
usually associated with the poorest survival. In addition, the inclu-
sion of the T4 category into the stage grouping IVa, which includes
any patients with LN metastases, points out that the TMN review-
ers postulated that in such patients the prognosis is independent to
the presence or absence of LN metastases. Yet, this assumption
remains to be demonstrated.One may argue that the current results
should be cautiously interpreted. Indeed, several series from Japan
have reported that the prevalence of the periductal infiltrating
subtype or mixed tumours, usually mass-formingplus periductal-
infiltrating, is significantly higher than the one observed in our
population.15,16 Although it is possible that some patients have been
misdiagnosed with an underestimation of the mixed forms, a fact
that might have determined a stage migration, it is also possible
that the gross pathology of IHC in Eastern and Western countries
differ significantly. Evidences suggests that in Europe IHC are
almost exclusively of the mass forming subtype.17,18 While the
prognostic significance of the new T4 category remains uncertain
the introduction of this specific T class might facilitate the acqui-
sition of oncologic information for future investigations.19
A limitation of the present study is that it was not possible to
compare all T classes and stage strata because of the limited
number of patients with ‘Tumour(s) perforating the visceral peri-
toneum or involving the local extra hepatic structures by direct
invasion’ (the sixth edition T4 and seventh edition T3 categories
corresponding, in pN0 patients, to stages IIIb and III, respec-
tively). Nonetheless, the rarity of such patients has been previ-
ously recognized.18 One possible explanation is that, in western
countries, an accurate reporting of the serosal invasion is lacking
or that such locally advanced tumours are rarely resected because,
at this stage of disease, the frequency with which peritoneal
implants are present is extremely high.
In conclusion, although the seventh edition of the TMN staging
system has introduced important changes resulting in a better
contrast, albeit marginally significant, between early stages and
the provision of a specific reporting of IHC of the periductal-
infiltrating subtype, its superiority to the sixth edition remains to
be confirmed.
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